Affiliations 

  • 1 Department of Surgery, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor 43400, Malaysia; email: dr.zubaidahnh@gmail.com
  • 2 Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA; email: schauerpr@mac.com
Annu Rev Med, 2020 01 27;71:1-15.
PMID: 31986081 DOI: 10.1146/annurev-med-053117-123246

Abstract

Metabolic surgery is increasingly becoming recognized as a more effective treatment for patients with type 2 diabetes (T2D) and obesity as compared to lifestyle modification and medical management alone. Both observational studies and clinical trials have shown metabolic surgery to result in sustained weight loss (20-30%), T2D remission rates ranging from 23% to 60%, and improvement in cardiovascular risk factors such as hypertension and dyslipidemia. Metabolic surgery is cost-effective and relatively safe, with perioperative risks and mortality comparable to low-risk procedures such as cholecystectomy, hysterectomy, and appendectomy. International diabetes and medical organizations have endorsed metabolic surgery as a standard treatment for T2D with obesity.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.